Natera partners with Angiex to use Signatera ctDNA test in AGX101 Phase I trial monitoring

Reuters2026/08/27 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Natera entered a Signatera collaboration with Angiex to track treatment response in Angiex’s Phase I AGX101 solid-tumor trial.
Agreement calls for longitudinal Signatera ctDNA testing during AGX101 dosing to assess molecular response alongside imaging.
AGX101 targets TM4SF1 to deliver a cytotoxic payload to tumor cells, also tumor-associated endothelial cells, aiming to hit tumor vasculature.
Data are intended to support development decisions for AGX101 by clarifying response when radiology results are uncertain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608270600BIZWIRE_USPR_____20260827_BW232786) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Natera partners with Angiex to use Signatera ctDNA test in AGX101 Phase I trial monitoring

You may also like

Crypto prices